top of page

The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease

Bill Sibold describes how Madrigal has prepared for the launch, visually illustrates how the medicine is meant to impact disease progression, and shares his opinion on whether GLPs could potentially compete in this indication one day in the future.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page